Meet the Team

Dr. Siegel founded GZP in 1999 from his consulting firm, Ground Zero Strategics, Ltd. He served as Consultant and then Chief Executive Officer of OXO Chemie Inc. from 1997 to 1999. Before he joined OXO Chemie, he was the Vice President, Regulatory Affairs and Bioethics for Medical Science Systems, Inc., now Interleukin Genetics. Prior to that he was Director of Regulatory Consulting Services and Principal Regulatory Scientist for Quintiles, Inc., in Research Triangle Park, North Carolina. Dr. Siegel has held positions as a Toxicology Reviewer at the US Food and Drug Administration and Food and Drug Branch, California Department of Health Services and, at the latter, was Supervising Toxicologist and Chief of Special Services. He has served in regulatory affairs and executive positions in both the pharmaceutical industry (Astra, Syntex, Medical Science Systems and OXO Chemie) and trade association environments. He attended the Waksman Institute of Microbiology where he earned both his Master and Doctor of Philosophy degrees in Virology and Molecular Biology. He is an Adjunct Professor in Health Sciences at the University of Queensland, Brisbane, Australia.

Ms. Templeton specializes in the development of corporate systems, including administrative, accounting and finance systems as well as the structure and execution of operational procedures, administration of human resource and benefit programs, and infrastructure building. This includes managing financial and patient progress data streams from clinical trials, developing project management SOPs and policies, and tracking medical product development information from disparate sources. In addition, she leads the Quality Assurance team for electronic regulatory submissions. She is also the primary contact for all contracting with Ground Zero Pharmaceuticals, Inc. Ms. Templeton’s financial background includes designing and implementing the accounting systems for both OXO Chemie AG (a multinational pharmaceutical corporation) and Interleukin Genetics, Inc., formerly Medical Science Systems, Inc. (a biotechnology firm), in addition to several start-up companies. She has also developed financial auditing systems for clinical trial programs. In addition, Ms. Templeton has been involved with business plan creation and production for M&A and venture capital firms. She has completed a Pharmaceutical and Medical Device Regulatory Certificate program through RAPS.

Ms. Mages is an experienced Life Sciences Business Developer with extensive relationships and knowledge, within the Southern California, Midwest, and Australian pharmaceutical, biotech, and medical device industries, in Business-to-Business Sales. She is adept at creating, building, and maintaining business relationships through cold calling/emailing, networking, and strategic marketing. In addition, she is a regular attendee at BIO US, BIO Europe, AusBiotech conference, SoCal BIO, and many other annual life science conferences. Previous roles have included business development leader and recruiter at Real Life Sciences and the Allegis Group. She holds a BBA in Marketing from the University of Wisconsin, Milwaukee, completed an International Business program from Griffiths University in Queensland, Australia, and received a Regulatory Affairs Certificate: Medical Devices and Pharmaceuticals (Dual) completed through the Regulatory Affairs Certificate Program at RAPS University.

With over a decade of experience, as a GZP Project Manager Ms. Murphy provides technical and regulatory project management to GZP client programs. Her expertise is in leading both small molecule and biologics programs through to technically acceptable electronic submissions and facilitating LifeCycle management of regulatory projects. In addition to being an expert in electronic publishing for US FDA submissions, she developed the standards and processes for Health Canada regulatory submissions while working at Cardinal Health. She previously served in the US Army and is currently enrolled in the RAPS Dual certificate program for Pharmaceuticals and Medical Devices.